MC
PKBO

Meteora Capital’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

Meteora Capital’s Portfolio PKBO Stock Details PKBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200,835
Closed -$1.98M – 520
2022
Q2 		$1.98M Buy
+200,835
New +$1.98M 0.38% 59

Other funds holding PKBO

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Meteora Capital's PKBO Position: Q3 2022 in Review

Meteora Capital sold out of Peak Bio, Inc. Common Stock (PKBO) in Q3 2022, closing a stake of 200,835 shares — an estimated $1.98M sold.

Meteora Capital first reported a position in PKBO in Q2 2022 and held it in 1 quarter. The position peaked at $1.98M in Q2 2022. 43 funds tracked by Wall St. Rank hold PKBO as of Q3 2022.

  • Meteora Capital reported no remaining Peak Bio, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Meteora Capital sold 200,835 Peak Bio, Inc. Common Stock shares in Q3 2022, an estimated $1.98M.
  • Meteora Capital first reported a position in Peak Bio, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Meteora Capital's Peak Bio, Inc. Common Stock position peaked at $1.98M in Q2 2022.
  • 43 funds tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q3 2022.

Based on Meteora Capital's 13F filing for Q3 2022, filed 14 Nov 2022.